Targeting B-cells in lupus nephritis: Should cautious optimism remain?

Nephrology Dialysis Transplantation

Volumn 28, Issue 1, 2013, Pages 7-9

  Rovin, Brad H ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; BELIMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB;

ADD ON THERAPY; ARTICLE; B LYMPHOCYTE; CELL SURVIVAL; DRUG TARGETING; HUMAN; HUMORAL IMMUNITY; INFECTION; INFERTILITY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; MEMORY CELL; METABOLIC DISORDER; OPTIMISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; IMMUNOLOGIC FACTORS; LUPUS NEPHRITIS;

EID: 84872224836     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs319     Document Type: Article

References (19)

1. Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112.
2. Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab (LUNAR) study. Arthritis Rheum 2012; 64: 1215-1226.
3. Weidenbusch M, Rommaie C, Schrottie A et al. Beyond the LUNAR trial: rituximab for refractory lupus nephritis. Nephrol Dial Transplant 2013; 28: 106-111.
4. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010; 237: 264-283.
5. Rovin BH, Stillman IE. Kidney. In: Lahita RG, Tsokos GC, Buyon J et al. (eds). Systemic Lupus Erythematosus, 5th edition. London: Elsevier, 2011, pp. 769-814.
6. Chen YE, Korbet SM, Katz RS et al. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008; 3: 46-53.
7. Singh JA, Wells GA, Christensen R et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; Issue 2. Art. No.:CD008794; doi:10.1002/14651858/CD008794.put 2.
8. Condon M, Griffith M, Cook HT et al. Treatment of class IV lupus nephritis with rituximab and MMF with no oral steroids is safe and effective. J Am Soc Nephrol 2010; 21: 625A.
9. Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886-1895.
10. Rovin BH, Parikh SV, Hebert LA et al. Induction therapy in severe lupus nephritis: can MMF be considered the drug of choice? Clin J Am Soc Nephrol 2012; (in press).
11. Chang A, Henderson SG, Brandt D et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol 2011; 186: 1849-1860.
12. Vital EM, Dass S, Buch MH et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3038-3047.
13. Sanz I, Lee FE-H. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6: 326-337.
14. Anolik JH, Barnard J, Owen T et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007; 56: 3044-3056.
15. Khan WN. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 2009; 183: 3561-3567.
16. Thien M, Phan TG, Gardam S et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20: 785-798.
17. Lesley R, Xu Y, Kalled SL et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20: 441-453.
18. Navarra SV, Guzman RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-731.
19. Furie R, Petri M, Zamani O et al. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-3930.